Omega Therapeutics

We are pioneering a new class of programmable #epigenomic mRNA medicines to modify gene expression pre-transcriptionally, addressing disease at its source. See our #EpigenomicControllers in action & learn more about our mechanism of action here: brnw.ch/21wGhDL

❓ What makes our approach different? #EpigenomicControllers are programmed to target unique sequences within the genome with high specificity to tune gene expression for a tailored duration. Learn more about the potential impact of our approach: bit.ly/3xiJzZo

Wishing all our #Omegans and their families a healthy, joyful, and peaceful holiday season! Thank you for your hard work, dedication, and passion throughout the year.

#ICYMI, we shared a poster at @AASLDtweets’ #TLM24 showcasing durable upregulation of HNF4α using an #EpigenomicController. This represents a potentially novel therapeutic strategy for the treatment of fibrotic liver disease. View the poster here: bit.ly/4eVuSeF

Currently available #obesity treatments focus on appetite management and may not be effective for every patient. At Omega, we’re partnering with @NovoNordisk to potentially reimagine obesity management using an #EpigenomicController. Read more here: bit.ly/4cgF53K

At Omega, we’re grateful for our dedicated team working to advance innovative #EpigenomicControllers for patients in need. We deeply appreciate the passion of our #Omegans and the values that drive us. #OmegaValues

At the 12th International #mRNAHealthConference & @AASLDtweet’s The Liver Meeting®, we shared exciting preclinical data showcasing durable upregulation of #GeneExpression by our #EpigenomicControllers. Read how this work advances our mission here: bit.ly/4fAkPMY

Today we announced our Third Quarter 2024 financial results, completion of our Phase 1 study and strategic updates. Learn more in our press release: bit.ly/3URA77S $OMGA

At #SITC2024, we presented a poster highlighting that controlled epigenomic upregulation of CXCL9 & CXCL10 in #HepatocellularCarcinoma promotes T-cell recruitment. This exemplifies the versatile capabilities of the OMEGA platform. Learn more here: bit.ly/491M6FX

Epigenetic modifications control DNA’s 3D structure without changing the genetic code. Our OMEGA platform uses this understanding to design therapeutic candidates that act pre-transcriptionally to regulate gene expression. Learn more about our science: bit.ly/4couGU9

What sets the OMEGA Platform apart? ✔️ #EpigenomicControllers, designed to be highly specific for target gene ✔️ Customizable delivery tailored for specific diseases ✔️ AI-driven approach enabling rapid design, development, & optimization Learn more: bit.ly/3zsae6I

Our CEO, Mahesh Karande, discusses key disruptors in the pharma industry in the latest issue of @medicine_maker. Read his thoughts about the groundbreaking rise of #mRNA as a therapeutic modality: bit.ly/4hequtx

Our goal was to create a platform that can precisely target and control gene expression, and we did just that. The OMEGA platform has the potential to address a wide range of diseases, including some that currently have no disease-modifying treatments: bit.ly/3XMBdCx

🎉 #Omegans took a well-deserved break from our busy days to connect, celebrate achievements, and embrace the spirit of unity at our annual Fall get-together. Cheers to teamwork and the values that keep us strong! #OmegaValues

#DYK that by 2030, 1 in 2 U.S. adults will live with #obesity? Currently available treatments are focused on managing symptoms, which is why we’re exploring the potential to manage obesity through #PrecisionEpigenomicControl with @NovoNordisk. More here: bit.ly/4cgF53K

We’re looking forward to presenting at these scientific conferences: 🎤 @sitcancer 39th Annual Meeting – 11/9 🎤 12th International #mRNAHealthConference – 11/12 🎤 @AASLDtweets’s 75th Annual Meeting – 11/17 Details here: bit.ly/3U4zsPR #SITC2024 @mrnaconference #TLM24

The OMEGA platform has the potential to target nearly any human gene, even those once considered undruggable. Our recent publication in @NatureComms showcases this potential, paving the way for transformative treatments. Read more here: bit.ly/3ZtPypU

#HepatocellularCarcinoma (HCC) is the most common type of adult primary #LiverCancer & incidence is on the rise. This #LiverCancerAwarenessMonth, we support those affected and advocate for further research. Learn more about how you can get involved: bit.ly/3V1r3LX

#Omegan Kathleen Davenport will be participating in a panel about commercial and product strategy considerations in early R&D at the New Product Planning Summit by @LifeSciEvents! Watch her panel session here: bit.ly/3ZtQDxY

On #WorldCancerResearchDay, we join others in raising awareness of the ongoing urgent need for research to improve outcomes for patients living with #cancer & provide hope to families. See how you can support: bit.ly/48onmH2 @WCRD24Sept

🎯 Our epigenomic controllers are designed with unmatched specificity. Each DNA-binding domain targets a single epigenomic zipcode or EpiZip, ensuring precise gene regulation. Learn more about the benefits of #EpigenomicControllers here: bit.ly/3xiJzZo